Patent Description:
Hyaluronic acid (HA), also known as hyaluronan or hyaluronate sodium, is a long-chain polysaccharide consisted of D-glucuronic acid and N-acetylglucosamine, with the disaccharide unit up to 25000KD. Tissues such as human subcutaneous tissue, epidermis, oropharyngeal mucosa, etc. contain a large amount of high-molecular-weight hyaluronic acid (HMW-HA). In other words, HMW-HA is the basic construction material for human skin, mucous membranes, subcutaneous tissues, etc., and it has the functions of water retention and moisturizing. The existing HA products in the market are mainly the products with HMW-HA as the main functional ingredient for facial care or facial cosmetology.

In recent years, a series of studies have suggested that LMW-HA and HMW-HA, which are distinguished by molecular weight, demonstrate functional differences in small animal experiments and cell level studies. The mainstream references have indicated that LMW-HA is a degraded byproduct of inflamed tissues and is co-located with the distribution of inflammation, and it has the function of inducing and promoting inflammatory responses. The main references include:.

<CIT> discloses the treatment of keloid scars, hypertrophic scars or burn scars with contracture includes administering low molecular weight hyaluronic acid to the keloid scar, hypertrophic scar or burn scar with contracture.

<CIT> discloses preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of at least one low purity or cosmetic grade complex carbohydrate selected from the group consisting of oligosaccharides, sialylated oligosaccharides, polysaccharides and glycosaminoglycans, and an effective amount of at least one transdermal or transmucosal carrier in an amount effective to deliver the complex carbohydrate into the blood stream.

However, the applicant's research achievements in recent years (<CIT>, <CIT>, <CIT>, <CIT>, <CIT>, <CIT>, <CIT>and <CIT>) suggest another possibility that LMW-HA fragments in vitro preparation have the function of inhibiting inflammation of skin and mucous membranes. According to these references, the role of the LMW-HA fragments in inhibiting inflammation may be related either to the extent of molecular size or to its manufacture method. Moreover, the comparative results of experiments on small animals, large animals and human also show that the function of the LMW-HA fragments may be completely different in small animals, large animals and human. For example, the above patent references indicated that the LMW-HA fragments with a molecular weight distribution of <NUM>-60KD could be prepared into in vitro preparations for topical use (such as daily necessities, hygiene products, cosmetics, skin care products, disinfecting products, etc.) to help alleviate or treat inflammation of skin and mucous membranes; whereas other's LMW-HA less than 10KD substantially did not have such effect. However, according to the recent patent <CIT>, LMW-HA less than 10KD produced by use of streptococci hyaluronidase digesting HA did not induce an inflammatory reaction, but LMW-HA greater than 10KD produced by Streptomyces hyaluronidase induced an inflammatory reaction, suggesting that the function of LMW-HA may also be related to the type of enzyme for digestion, namely manufacture methods which lead to differences in three-dimensional structure or molecular arrangement of HA fragments.

These contradictory research results suggest that it is difficult to determine the exact function of LMW-HA fragments at present. Perhaps the production mode, molecular weight, type of enzyme for digestion, the mode of use, etc. of LMW-HA fragments may affect their functional performance, but in addition to these known possible factors, there are many other unknown factors for the researchers currently, for example, reliable experimental results of large animals are not available. Therefore, although the insiders pin their hope on the medical value of LMW-HA, it is difficult to predict the clinical research and success of LMW-HA, and it is quite difficult to determine the clinical indications. A feasible and effective LMW-HA in vitro preparation has been obtained in previous researches, but due to the complex internal environment of human, the LMW-HA in vivo injection may be completely different from the in vitro preparation, whereas the role may not be the same in human, large animals and small animals. Therefore, it requires for further verification by clinical studies. In addition, LMW-HA used for in vivo injection will have higher requirements on more aspects, for example, it shall meet the requirements of high purity, no severe injection or after injection pain and no allergic reaction, and the indications and side effects, as well as the dose of each injection, the way of injection, etc. shall be specified. It will have great scientific significance and application value in solving the above unpredictable problems.

The invention aims to provide -pharmaceutical compositions comprising LMW-HA fragments. and their uses in methods of treatment as defined in the appended claims. The invention at least has the following advantages:.

The above are only the summarization on the technical schemes of the invention. In order to get clearer understanding about the technical means, the invention will be further explained in details by combining with drawings and embodiments.

As mentioned above, based on the current industrial research achievements, it is difficult to determine the exact functions of LMW-HA. And there are even contradictive functional phenomena according to the results of current scientific experiments, whereas the mechanism of action for such phenomena is still completely unclear. On the basis of previous researches (<CIT>, <CIT>, <CIT>, <CIT>, <CIT>, <CIT>, <CIT> and <CIT>), the invention hopes to further explore the unknown functions of LMW-HA fragments by designing studies on small animals, large animals and human. According to the experimental studies on small animals and large animals, the inventor finds that the LMW-HA fragments in injection use have unclear therapeutic effect on species of small animals as well as large animals, at the same time. The results of clinical studies on human also unexpectedly suggest that the LMW-HA fragments have a series of new applications in injection use, and such applications can be reflected by more convenient ways of injection (such as injection via abdominal subcutaneous fat layer or at painful/itching point or diseased sites).

The experimental results of clinical studies show that the LMW-HA fragments have an unexpected effect of treating multiple diseases or alleviating symptoms in injection use. Specifically, the multiple diseases include solid tumors (such as lung cancer, pancreatic cancer, oral cancer, meningioma, gastric cancer, ovarian cancer, etc.), xerophthalmia, muscae volitantes, conjunctival diseases, vitreous opacity, vitreous detachment or impaired vision induced by vitreous opacity, myofascitis, muscle and tendon injury, hyperosteogeny, bone spur, protrusion of intervertebral disc, diseases of lumbar spinal diseases and cervical vertebra, gout, arthritis, ankylosing spondylitis, cardiovascular diseases (including coronary heart disease and the complications after intravascular stent), dysmenorrhea, endometriosis, adenomyosis, periodontal disease, dental ulcer and guttural diseases, herpes zoster, neurodermatitis, psoriasis, eczema, eczema herpeticum, pompholyx, burn, trauma, surgical wound, etc., as well as abdominal mucous membrane adhesion, pelvic mucous membrane adhesion, etc. induced after operation or peritoneal dialysis; besides, it can prevent the transfer of solid tumors, accelerate the functional rehabilitation after cerebral infarction or cerebral hemorrhage, enhance or recover physical strength and energy after chemotherapy or treat the side effects after chemotherapy, and it can also quickly alleviate pain or pruritus; according to these results, LMW-HA fragments have a great application value in preparing drugs or adjuvant drugs for treating relevant diseases.

Besides, the experimental results also suggest that LMW-HA fragments reduce subcutaneous fat, especially that of human head, face and neck. At the same time, they also have the efficacies on facial cosmetology and anti-aging. The existing HMW-HA in the market is used by facial injection, and it is injected into dermal wrinkles and concaves or the site to be smoothed in the form of filler to realize the application for facial cosmetology, such as filling concaves, removing wrinkles, moulding, etc.; the LMW-HA fragments compositions in the invention differ in that they can be injected via abdominal subcutaneous fat layer while in use instead of facial injection, which will not result in pain and facial inflammation. Therefore, the LMW-HA fragments also have an outstanding application potential in the fields of body care, anti-aging and cosmetology.

The LMW-HA fragments used in the compositions of the invention and in the above experiments are obtained by the following specific manufacture method: the LMW-HA fragments are HA fragments with a molecular weight distribution of <NUM>-60KD obtained from HMW-HA digested directly by recombinant human hyaluronidase PH20. In the process of production, recombinant human hyaluronidase PH20 can be produced by Chinese hamster ovary (CHO) cells or yeast or plant expression, for example, it has been recorded in the previous patent documents (<CIT>, <CIT> and <CIT>) that glycosylated recombinant human hyaluronidase PH20 is produced by using the Chinese hamster ovary (CHO) cells.

In order to ensure the safety in injection use, high purity is preferred for recombinant human hyaluronidase PH20 (preferred with a purity > <NUM>%), and a medical purity ><NUM>% is preferred for HMW-HA raw material. In practical production, raw material of high purity can be used directly, or recombinant human hyaluronidase PH20 and HMW-HA raw material of low purity can also be used for the subsequent steps after purification. Besides, on completion of the enzyme digestion reaction, recombinant human hyaluronidase shall also be inactivated, following by inactivating viruses and filtering or inactivating bacteria. By combining with the results of clinical studies, it has been found that HA fragments containing protein residue of recombinant human hyaluronidase have no allergic reaction and side effect in injection use, but it is suggested to separate and remove the protein residue of recombinant human hyaluronidase PH20 after inactivation.

For convenience of injection use, LMW-HA fragments are prepared into a liquid injection for use during the experiments, and the injection contains an effective dose of HA fragments with a molecular weight distribution of <NUM>-60KD. In practical application, the LMW-HA fragments for injection use can be prepared into other forms of injection, for example, they can also be prepared into sterile powder or concentrated solution which will be mixed into solution before use.

The invention will be explained through the specific embodiments below. It shall be understood that the embodiments described here are only for describing and explaining the invention. Besides, unless otherwise specified, the drugs or reagents involved in the following embodiments can all be purchased from normal business channel. Unless otherwise specified, the experimental techniques or operating methods involved in the following embodiments all refer to the known conventional experimental techniques or operating methods in this field.

Objective: To produce recombinant human hyaluronidase PH20 and prepare LMW-HA fragments injection.

Methods: Based on the methods recorded in the patent documents No. <CIT>, <CIT> and <CIT>, glycosylated recombinant human hyaluronidase PH20 was produced using Chinese hamster ovary (CHO cells), including: Artificially synthesize the gene cDNA of glycosylated recombinant human hyaluronidase PH20, insert it into the empty GC-rich expression vectors of pMH3, pMH4 and pMH5 to construct the expression vectors of pMH3-PH20, pMH4-PH20 and pMH5-PH20 (the expression vectors were constructed using the methods recorded in the patent document No. <CIT> so as to extremely highly express recombinant protein); then transfer the expression vectors of pMH3-PH20, pMH4-PH20 and pMH5-PH20 into the CHO-S cell line, and screen the CHO-S cell clones for cell lines that express the highest level of human hyaluronidase PH20. Then, the cell lines that express the highest level of human hyaluronidase PH20 was scaled up for large-scale culture in the shaking cell culture bioreactor shown in <FIG>; filter the harvested condition medium containing PH20 through <NUM> filtration membrane, then separate by <NUM>-<NUM> steps using ion column, hydrophobic column and hydroxyapatite column etc., then perform the steps of bacterial filtration, virus filtration and inactivation, ultrafiltration for preparation of concentrated purified bulk of sterile and virus-free glycosylated recombinant human hyaluronidase PH20 with a purity ><NUM>%.

Use an enzyme digestion and blending bioreactor with a working volume of <NUM> featured with cleaning and sterilization in-place , and prepare injection-grade HA raw material with a molecular weight distribution of <NUM>-1200KD; add and blend the injection-grade HA raw material of a molecular weight distribution of <NUM>-1200KD into injection-grade pure water for intensive dissolution one time or several times; then add sodium chloride, magnesium ions and recombinant human hyaluronidase until reaching their final concentration of <NUM>-<NUM>, <NUM> and <NUM>,<NUM>-<NUM> units (about <NUM>-20µg) per <NUM> of HMW-HA respectively in order, mix them completely, and react at <NUM> for <NUM>-<NUM> until that the molecular weight of HA fragments reaches 10KD-60KD. Add sodium chloride (final concentration of <NUM>-<NUM>) to regulate the osmotic pressure to <NUM>-300mOsm/L, then heat it at <NUM>-<NUM> for <NUM>-<NUM> (thermal inactivation of recombinant human hyaluronidase, partial bacterial inactivation and virus inactivation (by simultaneously reducing the pH level), and then remove bacteria by <NUM> filtration. Solution <NUM> was obtained after the filtration, and it contained the residue of inactivated recombinant human hyaluronidase. Further, remove the protein residue of inactivated recombinant human hyaluronidase PH20 in Solution <NUM> by using affinity column chromatography, precipitation, ultrafiltration and dialysis in order or respectively to obtain Solution <NUM> containing 10KD-60KD HA fragments, sodium chloride and magnesium ions only.

In order to research the production method of injection preparation and clearly know the effect of recombinant human hyaluronidase after inactivation, two injections containing HA fragments were obtained according to the above production method in the embodiment: one based on Solution <NUM> contains the protein residue of inactivated recombinant human hyaluronidase PH20 without enzyme activity (the amount of the protein residue shall be controlled in production practice for safety and reliability in use). The other one based on Solution <NUM> does not contain the protein residue of inactivated recombinant human hyaluronidase PH20.

The glycosylated recombinant human hyaluronidase with a purity > <NUM>% and produced from CHO cells was obtained (<FIG>);
The following two injections containing LMW-HA fragments were prepared, and the injections were filled in small bottles and prepared into HA fragments with an effective dose of <NUM> per bottle (<FIG>). After final filling and packaging, the injections can be stably stored at <NUM>-<NUM> or -<NUM>-<NUM> or room temperature for <NUM> years.

Injection <NUM>: Each <NUM>-<NUM> contained <NUM> of HA fragments with a molecular weight distribution of 10KD-60KD and < 20µg of protein residue of inactivated recombinant human hyaluronidase PH20 without enzyme activity (endotoxin < <NUM> IU/ml, sterile, virus-free), the final concentration of sodium chloride was <NUM>-<NUM>, and the final concentration of magnesium ions was <NUM>.

Injection <NUM>: Each <NUM>-<NUM> contained <NUM> of HA fragments with a molecular weight distribution of 10KD-60KD but did not contain protein residue of inactivated recombinant human hyaluronidase PH20 (endotoxin < <NUM> IU/ml, sterile, virus-free), the final concentration of sodium chloride was <NUM>-<NUM>, and the final concentration of magnesium ions was <NUM>.

Conclusion: The results suggest that HA fragment Injection <NUM> containing protein residue of recombinant human hyaluronidase and Injection <NUM> not containing protein residue of recombinant human hyaluronidase are successfully prepared, and the production technology for injection of HA fragments is established.

Besides, it has been found in the following experiments that the two forms of injections have basically the same therapeutic effect, and have no allergic reaction and other side effects (which meets the FDA standards for biological medicine and Type III medical devices), suggesting that inactivated recombinant human hyaluronidase PH20 has no influence on the effect and safety of injection of HA fragments. HA fragments with a molecular weight distribution of 10KD-60KD is the main active ingredient in the injections, and such bioactive HA fragments (the LMW-HA fragments) are called as B-HA for short).

Objective: To study bacterial inhibition activity, in vitro cellular activity, and activity in small animals of the above HA fragment injections (Injection <NUM> and Injection <NUM>).

Methods: Dilute Injection <NUM> and Injection <NUM> with normal saline to double volume for study bacterial inhibition activity, in vitro cellular activity, and activity in small animals of the above HA fragment injections (Injection <NUM> and Injection <NUM>).

Results: <FIG> showed that Injection <NUM> inhibited the cloning and growth of porphyromonas gingivalis, suggesting that the HA fragment injection was not favorable for the growth of porphyromonas gingivalis (note: the negative control was normal saline, and the positive control was antibiotic metronidazole);.

Background: The research in Embodiment <NUM> indicates that B-HA may realize the actions of anti-inflammation, relieving pain and itching, and effectively treating various diseases and morbid states by a new action mechanism of accelerating the secretion of anti-inflammatory cytokine IL-<NUM> through interaction with TLR4. The action mechanism provides a theoretical foundation for B-HA in the unexpectedly effective treating for various diseases and morbid states.

Objective: To study the effects of the above HA fragment injections (Injection <NUM> and Injection <NUM>) on inflammation in small animals and large animals.

Research Background: Research literatures show that the bioactivity or function of HA or its fragments is not only related to the molecular weight and/or the manufacture method, but also to the species of animals. The studies in small animals such as mice suggest that the bioactivity of HA fragments (LMW-HA) promotes inflammations, but the studies in large animals and human suggest that the bioactivity of HA inhibits inflammations. Therefore, different species of animals including small and large are employed in this embodiment to study the bioactivity of the above HA fragment injections (Injection <NUM> and Injection <NUM>) on different types of inflammation. The results demonstrated that HA fragment injection has an anti-inflammatory activity in large animals.

A total of <NUM> female ICR mice were used in this experiment. Dissect the cervical spinal cord and cut it off with a <NUM># scalpel. Protect the cut spinal cord wounds with PEG MW <NUM> cell membrane fusogen, then suture the muscle and skin, and provide nutrition via caudal veins of the mice <NUM> times a day using venous high-nutrient normal saline and HA fragment injection + venous high-nutrient normal saline. After <NUM> weeks postoperatively, all the mice had partial neurobehavioral recovery, and then all the mice were killed. Cryopreserve the cut spinal cord wounds using dry ice and perform cryosection, then fix them with <NUM>% formalin and perform immunohistochemical staining using Anti-neurofilament <NUM> and DAPI, and examine axonal sprouting using a fluorescent or confocal microscope.

Results: Table <NUM> showed the inflammations of cervical wounds, the axonal sprouting on the surface and the wound healing of spinal cord wound in the mice treated by the above HA fragment Injection <NUM> and control mice. The situations of Injection <NUM> were basically the same as those of Injection <NUM> without significant differences, and those was not shown here.

Conclusion: The above HA fragment injections (Injection <NUM> and Injection <NUM>) cannot significantly control the inflammation of cervical wound and cannot significantly promote the axonal sprouting and wound healing of spinal cord wound in mice, indicating that the HA fragment injections have no obvious anti-inflammatory effect on mice as a species of small animals.

Ten C57/BL6 mice of age <NUM>-week were used in this experiment, and mice models of myocardial inflammation were produced using angiotensin II (<NUM> ng/kg per minute) for <NUM> consecutive days. With <NUM> mice in each group, Group <NUM> was injected with HA fragment injection + saline, and Group <NUM> was injected with saline. After <NUM> days, heart sections were stained with hematoxylin, eosin and Masson trichrome for histochemical staining to observe the infiltration of myocardial inflammatory cells.

Results: Table <NUM> showed the effect of HA fragment Injection <NUM> and control saline on the myocardial infiltration of inflammatory cells of the mice. The effect of Injection <NUM> was basically the same as those of Injection <NUM> without significant differences, and those were not shown here.

Conclusion: The above HA fragment injections (Injection <NUM> and Injection <NUM>) significantly promote the infiltration of myocardial inflammatory cells induced by angiotensin II in mice, indicating that the HA fragment injections have the bioactivity in promoting inflammation in mice as a species of small animals.

Six healthy beagle dogs were used in this experiment, weighing <NUM>±<NUM>. After <NUM> days of pre-feeding, the <NUM> dogs were randomly divided into blank control group (n=<NUM>), B-HA low-dose group (n=<NUM>) and B-HA high-dose group(n=<NUM>). The experimental dogs were fasted for <NUM> and deprived of water for <NUM> before operation. At <NUM> before operation, the dogs in the high-dose group were subcutaneously injected with the above HA fragment injection <NUM>/kg on the back; the dogs in the low-dose group were subcutaneously injected with the above HA fragment injection <NUM>/kg on the back; the dogs in the blank group were not injected. Perform anesthetization and conventional preparation of operative site, and fix them in a supine position, conventionally open the abdominal cavity along the midline of abdomen at <NUM> behind the umbilicus, search the cecum and find the ileocecal junction, take the ileum at about <NUM> from the ileocecal junction out of the abdominal cavity, isolate and conventionally cut off the intestinal canal, and perform end-to-end anastomosis in a full-thickness continuous suture. On completion of suturing, inject normal saline into the anastomotic part, check the airtightness of the anastomotic part, apply <NUM> of the above HA fragment injection at the operative site in the low-dose group and the high-dose group, and then suture the abdominal wall layer by layer. Record the operative practice in details during the operation. The dogs were fasted for <NUM> days and were then given a liquid diet (adding appropriate oral liquid in yogurt for salt supplementation) with increasing amounts, the animals were fed with soft dog food after defecation and gradually transited to normal dog food, and postoperative observation was performed every morning for <NUM> consecutive days.

Results: <NUM>. Postoperative observation: The postoperative conditions of the dogs were observed, and it was found that in the untreated blank group, the mental state and activity state were significantly worse than those in the experimental groups within <NUM> days postoperatively, fever occurred within <NUM> days postoperatively, and the body temperature, mental state and activity state recovered to the preoperative levels from Day <NUM> postoperatively to the end of monitoring; <NUM>. In the HA fragment injection low-dose and high-dose groups, the postoperative mental state and activity state were not significantly different from those postoperatively, indicating that the HA fragment injection effectively controlled the postoperative fever, abdominal inflammation and pain induced by system inflammatory factors, it did not affect the activity and promoted the recovery of intestinal peristalsis, and it reduced the possibility of abdominal adhesion; <NUM>. At Day <NUM> postoperatively, exploratory laparotomy was performed in each group, there was no wound healing disorder by visual inspection, such as intestinal anastomotic fistula and intestinal stenosis or obstruction. In the blank group, the adhesion of operative site with greater omentum was observed. In the HA fragment injection low-dose and high-dose groups in Embodiment <NUM>, the adhesion of operative site with greater omentum was not observed. Local adhesion of surgically wounded site with adjacent intestinal tract could be observed in all the blank group and the HA fragment injection low-dose and high-dose groups, and it was speculated that the local adhesion of surgically wounded site with adjacent intestinal tract could be effectively obstructed by the gel physical method of high-viscosity HA fragment.

Conclusion: The subcutaneous injection of HA fragment injection (Injection <NUM>) and administration by applying on the operative site can significantly improve fever, abdominal inflammation and pain induced by released systemic inflammation factors after intestinal anastomosis operation in dogs. Besides, these therapeutic actions do not negatively affect physical activities and promote the recovery of intestinal peristalsis, and reduce possible abdominal adhesion. In addition, side effects including wound healing disorders are not observed, such as intestinal anastomotic fistula and intestinal stenosis or obstruction. Results indicate that the above HA fragment injections play a role in preventing and treating local abdominal adhesions by their anti-inflammatory action in dogs as a species of large animals.

Six healthy beagle dogs were used, weighing <NUM> ± <NUM>. After <NUM> days of pre-feeding, the <NUM> dogs were randomly divided into blank control group (n=<NUM>) and HA fragment injection treatment groups (n=<NUM>). The experimental dogs were fasted for <NUM> and deprived of water for <NUM> preoperatively. At <NUM> preoperatively, the dogs in the HA fragment Injection <NUM> treatment group <NUM> and the HA fragment Injection <NUM> treatment group <NUM> were injected subcutaneously with <NUM>%/kg normal saline containing <NUM>% B-HA, and those in the blank group were injected subcutaneously with normal saline. Perform anesthesia and conventional preparation of operative site, incise for <NUM> on both sides of the midline on the back without suture, and contaminate the wound with contaminated soil. After operation, the dogs in the treatment groups <NUM> and <NUM> were injected subcutaneously with <NUM>/kg HA fragment injection + normal saline on the back every day, whereas those in the blank group were injected subcutaneously with normal saline on the back every day, and postoperative observation was performed every morning for <NUM> consecutive days.

By the postoperative observation for <NUM>-<NUM> days, the inflammation and healing of back wounds of the dogs in the HA fragment injection treatment groups <NUM>, <NUM> were significantly better than those in the saline treatment group.

Conclusion: The subcutaneous injection of HA fragment injections effectively controls the back wound inflammation of the dogs and promotes the back wound healing of the dogs, indicating that the HA fragment injections have an anti-inflammatory effect on dogs as a species of large animals.

<NUM> pet cats with oral wound inflammation were selected from a pet hospital, <NUM> cats were treated by local injection of <NUM> of HA fragment Injection <NUM> (treatment group <NUM>), <NUM> cats were treated by local injection of <NUM> of HA fragment Injection <NUM> (treatment
group <NUM>), once a day for <NUM> consecutive days, and the therapeutic effect was observed every morning. The other <NUM> pet cats with oral wound inflammation from the pet hospital were not treated as the control group.

The observation at Day <NUM>-<NUM> after the treatment with HA fragment injections showed that the local injection of HA fragment injection <NUM> or injection <NUM> significantly controlled the redness and swelling of wound as the oral wound inflammation of the pet cats, and had a rapid anti-inflammatory effect on wound.

Conclusion: The HA fragment injections have a rapid anti-inflammatory effect on the oral wound inflammation of pet cats, and can significantly control the redness, swelling and pain of wounds, indicating that the HA fragment injections have an anti-inflammatory effect on cats. A Study of controlling inflammatory cough in cows.

Seven cows with inflammatory cough received by a veterinary hospital were treated by subcutaneous injection of <NUM> of HA fragment Injection <NUM>, once a day for <NUM> consecutive days, and the therapeutic effect was observed every morning. Another <NUM> cows with inflammatory cough received by the veterinary hospital were not treated as the control group.

The observation at Day <NUM>-<NUM> after treatment with HA fragment Injection <NUM> showed that the inflammatory cough of the cows could be controlled at <NUM> hours after subcutaneous injection of <NUM> of HA fragment Injection <NUM>, and it could be completely cured after <NUM> days of treatment.

Conclusion: The HA fragment injection is effective in treating inflammatory cough in cows, indicating that the HA fragment injection has an anti-inflammatory effect on cows as a species of large animals.

Seven horses with arthritis received by a veterinary hospital were treated by subcutaneous injection of <NUM> of HA fragment Injection <NUM>, once a day for <NUM> consecutive days, and the therapeutic effect was observed every morning.

At Day <NUM>-<NUM> after treatment with HA fragment Injection <NUM>, the observation on walking abnormalities caused by arthritis pain showed that the walking abnormalities caused by arthritis pain in the horses were significantly alleviated at Day <NUM> after subcutaneous injection of <NUM> of HA fragment Injection <NUM>, and the effect was more significant after <NUM> days of treatment.

Conclusion: The HA fragment injection is effective in treating arthritis pain of horses as large animals, indicating that the HA fragment injection has an anti-inflammatory effect on hoses as a species of large animals.

Summary on the researches in Embodiment <NUM>: According to the research results in Embodiment <NUM>, the research results of the function of LMW-HA fragments are completely different in mice and large animals, and thus it is predicted that the research results of the function of LMW-HA fragments in humans may be completely different from those in mice.

Research Background: According to the above researches in Embodiment <NUM>, some researches on function of HA or its fragments using mice described in previous references cannot represent the research results on function of HA or its fragments in large animals and human, and the above LMW-HA fragment injections have "unexpected" different functions for human.

Objective: To study the anti-aging effect and safety of Injection <NUM> or B-HA injection (experiment group <NUM>) containing protein residue of recombinant human hyaluronidase PH20 and Injection <NUM> (experimental group <NUM>) not containing protein residue of recombinant human hyaluronidase PH20 in the above Embodiment <NUM> on human facial cosmetology.

Methods: The HA fragment injection containing protein residue of recombinant human hyaluronidase PH20, i.e., HA fragment Injection <NUM> (B-HA injection) in Embodiment <NUM>, was used as the experimental group <NUM> to carry out a clinical study among <NUM> subjects (with the mean age of <NUM>±<NUM> years, <NUM> males and <NUM> females) with various diseases, subclinical problems or aging and aging-related diseases in current China's environment of air pollution, drinking water pollution and work stress; the HA fragment injection not containing protein residue of recombinant human hyaluronidase PH20, i.e., HA fragment Injection <NUM> in Embodiment <NUM>, was used as the experimental group <NUM> to carry out a clinical study among <NUM> subjects (with the mean age of <NUM>±<NUM> years, <NUM> males and <NUM> females) with various diseases or subclinical problems in current China's environment of air pollution, drinking water pollution and work stress or aging and aging-related diseases; they were injected with <NUM> (it refers to <NUM> of HA fragments with a molecular weight distribution of 10KD-60KD contained in the injection, the same below) via abdominal subcutaneous fat layer, <NUM>-<NUM> times a day for at least <NUM> consecutive days;
The cosmetic effects of the two injections (<NUM> and <NUM>) were compared by observing the facial features or pictures of the subjects before and after treatment (score: ineffective, undetermined, obviously effective), and the safety of the injection was evaluated by means of doctor's inquiry about the subject's feeling, symptoms, physical examination and laboratory tests, namely, whether there were side effects or not, including pain at the injection site, physical discomfort before and after injection, mental state and physical strength, and changes in original physical pain, original physical diseases and various original subclinical problems.

In addition to the above cosmetic effects, safety and side effects, it was also found that <NUM> cases felt comfortable and short period of sleepy after injection via abdominal subcutaneous fat layer; the sleepiness lasted for <NUM>-<NUM>, wherein, <NUM> cases slept for <NUM> after the first injection, and the energy and physical strength enhanced significantly after waking up; the other <NUM> cases did not feel sleepy any more after injection for twice.

Unexpectedly, <NUM> of all the <NUM> subjects felt an enhancement in energy and physical strength at <NUM> after injection via abdominal subcutaneous fat layer, demonstrated by the desire to talk, wash dishes, cook, walk, plan to travel, work and no desire to rest, etc., which lasted for <NUM>-<NUM> days.

<NUM> of the <NUM> subjects (including <NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>) suffered from different pains in shoulders, back, waist, legs and arm, and unexpectedly, they all felt that the pains were relieved at <NUM> after injection via abdominal subcutaneous fat layer. Among them, <NUM> cases were additionally injected with <NUM> at the local painful site, and the pain began to relieve at <NUM> after the injection, which was equivalent to the effect of the previous anesthesia treatment by local injection of lidocaine combined with prednisone complained by <NUM> cases.

<NUM> of the <NUM> subjects (including <NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>) suffered from itching of different degrees, and unexpectedly, they all felt that the itching was relieved or disappeared at Day <NUM> after injection via abdominal subcutaneous fat layer.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indications of myofascitis and old sports injuries of the HA fragment injections (Injection <NUM> and Injection <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indications of myofascitis and old sports injuries.

Rapid and effective treatment for myofascitis and old sports injuries: Myofascitis and old sports injuries are diseases related to sports injuries and senile degeneration, and the pathogenesis is not fully clear. There are professional chiropractors specialized in treating these diseases in the United States, whereas there is still no curative method at present.

Among the <NUM> subjects, we analyzed <NUM> cases of myofascitis in waist, back, neck and upper and lower limbs (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>) and <NUM> cases of old sports injuries (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

Among them, a <NUM>-year-old male subject had suffered from myofascitis for <NUM> years due to old sports injury for <NUM> years. It attacked when days became cold every year, the pain was very afflicting, and certain muscular movements may also cause the pain, and the range of activity was limited for neck and back. The pain was relieved at <NUM> after injection of <NUM> via abdominal subcutaneous fat layer, and then the effect was better by additional deep injection of <NUM> at the local pain points of neck and back. After <NUM>×<NUM> of injections within <NUM> months, the pain point and nodule on the back disappeared, and the thickness of neck and back muscles became thinner, without relapse within <NUM> months. The results showed that in addition to pain relief, the HA fragment injections finally solved the old sports injury and inflammatory lesions of myofascitis, realizing the purpose of recombination and regeneration of muscles and muscular fasciae.

Conclusion: The HA fragment injection via abdominal subcutaneous fat layer or at pain point or diseased site effectively treats painful myofascitis as well as muscle and tendon injuries in waist, back, neck and shoulders.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indications of bone spur and the protrusion of intervertebral disc or diseases of lumbar spinal diseases and cervical vertebra of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indications of bone spur and the protrusion of intervertebral disc or lumbar spondylosis, back disease and cervical spondylosis.

HA fragment injections can achieve rapid and effective treatment of bone spur and the protrusion of intervertebral disc or lumbar spondylosis, back disease and cervical spondylosis. Bone spur and the protrusion of intervertebral disc or lumbar spondylosis, back disease and cervical spondylosis are diseases related to senile degeneration and sports injuries, the pathogenesis is not fully clear, and there is still no curative method at present. Among the <NUM> subjects, we analyzed <NUM> cases of hyperosteogeny and bone spur in waist, back and neck (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

Among them, a <NUM>-year-old female subject suffered from hyperosteogeny and bone spur in waist, back and neck for <NUM> years. It attacked occasionally with very afflicting pain, which may also by caused by certain muscular movements. The range of activity was limited for neck and back, accompanied by the numbness of upper limbs and descending working ability. After injection of <NUM> via abdominal subcutaneous fat layer on Day <NUM>, the subject complained that the pain was relieved by more than <NUM>%, and she could make dumplings and cook in the kitchen; after injection of <NUM> on Day <NUM>, the subject complained that the pain was relieved by more than <NUM>%; and after injection of <NUM> on Day <NUM>, the subject complained that the pain was relieved by more than <NUM>%. After <NUM>×<NUM> of injections within <NUM> months, it did not relapse anymore. The results showed that in addition to pain relief, the HA fragment injections finally started the recombination and regeneration of the inflammatory lesions of old sports injury.

Among them, another <NUM>-year-old female subject suffered from hyperosteogeny and bone spur in neck for <NUM> years. The range of activity was limited for neck and back. It attacked occasionally with afflicting pain and was accompanied by the feeling of facial numbness, and certain muscular movements may also cause the pain, accompanied by the numbness of upper limbs and descending working ability. After injection of <NUM> via abdominal subcutaneous fat layer on Day <NUM>, the subject complained that the pain was relieved by more than <NUM>%; and after injection of <NUM> on Day <NUM>, the subject complained that the pain was relieved by more than <NUM>%. After <NUM>×<NUM> of injections within <NUM> months, it did not relapse any more. The results showed that in addition to pain relief, the HA fragment injections also started the recombination and regeneration of the inflammatory lesions of old sports injury. Note: All of the above subjects continued the treatment for more than <NUM> months to wait for the result of relapse or not.

Among them, another <NUM>-year-old male subject suffered from combined lumbar spondylosis, back disease and cervical spondylosis for <NUM> years. The pain was afflicting and accompanied by movement disorders, and he prepared to hospitalize for operation. He was injected with the HA fragment injection via abdominal subcutaneous fat layer for <NUM>×<NUM> within <NUM> months, and he could walk and swim without pain, indicating that the conservative non-surgical treatment was successful; it also suggested that the HA fragment injection could finally cure the inflammatory lesions of old sports injury and promote the recombination and regeneration of tissues.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer or at pain point or at diseased site is used for effectively treating the painful hyperosteogeny, bone spur, the protrusion of intervertebral disc, and the lumbar spondylosis, back disease and cervical spondylosis.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indications of vitreous opacity and vitreous detachment of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indications of vitreous opacity and vitreous detachment.

HA fragment injection in rapid and effective treatment of vitreous opacity: Vitreous opacity is a senile degenerative disease, the pathogenesis of which is not fully clear, and there is still no curative method at present. Vitreous opacity also known as muscae volitantes will further develop into vitreous detachment that impairs the fundus and affects the vision. Among the <NUM> subjects, we analyzed <NUM> cases of vitreous opacity and vitreous detachment (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

A <NUM>-year-old female subject was treated by <NUM> of HA fragment injection via abdominal subcutaneous fat layer for the need of facial comestic treatment, and <FIG> showed the laboratory diagnosis of the subject with vitreous opacity and vitreous detachment. After injection, it was occasionally found that the vision was ameliorated on Day <NUM>, and the spots of muscae volitantes for eyes became smaller on Day <NUM>; she was injected with <NUM>×<NUM> every <NUM> days continuously. The vision kept ameliorating (from <NUM> to <NUM>) and the spots of muscae volitantes became thinner and lighter continuously, without obvious relapse within <NUM> months. The results showed that the HA fragment injection could rapidly and effectively treat vitreous opacity (muscae volitantes) and vitreous detachment surprisingly.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating muscae volitantesor vitreous opacity and the vitreous detachment and diminution of vision induced by them.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of wound scars with itching (chronic inflammation) and pain (inflammatory pain) of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of wound scars with itching (chronic inflammation) and pain (inflammatory pain).

HA fragment injections in the treatment of wound scars with itching (chronic inflammation) and pain (inflammatory pain): The small wounds of people with scar diathesis can gradually form large scars and become thickening and itching continuously. The therapeutic targets are to relieve the itching and reduce the scar thickening; the scars formed after extensive burns without skin grafting continue to thicken with itching and chronic inflammation ( <FIG>), and the therapeutic targets are to relieve the itching, eliminate the inflammation and reduce the scar thickening; surgical wounds mainly have redness, pain, inflammatory reactive exudation and secondary infection, and therapeutic targets are to accelerate healing and reduce the scar formation. Among the <NUM> subjects, we analyzed <NUM> cases of wound scars with itching (chronic inflammation) and pain (inflammatory pain) (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

A <NUM>-year-old female subject had extensive burns without skin grafting <NUM> ago. She suffered from serious itching and difficulty in falling asleep, and there were inflammations around the scars. At Day <NUM> after <NUM>×<NUM> HA fragment injections, the scar became thinner, the inflammations around scar disappeared, the itching and the pain was significantly relieved; After <NUM>×<NUM> of HA injections continuously, the scar and the peripheral skin were significantly ameliorated, including that the scar became thinner, the inflammations disappeared, and the itching was relieved but did not completely disappear (<FIG>).

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating extensive burns, traumatic scars and scars of surgical wound accompanied by inflammations, itching and pain.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of abdominal mucous membrane adhesion after operation or peritoneal dialysis of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical probes of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of abdominal mucous membrane adhesion after operation or peritoneal dialysis.

HA fragment injections in rapid and effective treatment of abdominal mucous membrane adhesion after operation or peritoneal dialysis: Surgical injury, abdominal dialysis, etc. can almost cause abdominal mucosal inflammations and adhesions, and can cause symptoms and pathological changes depending on the severity, including abdominal pain, abdominal tenderness, abdominal mass and intestinal obstruction. At present, there is still no feasible way to eradicate abdominal adhesions. Among the <NUM> subjects, we analyzed <NUM> cases of abdominal mucous membrane adhesion after operation or dialysis (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

A <NUM>-year-old female subject began to eat non-liquid food <NUM> month after subtotal gastrectomy and peripheral lymph node dissection, and then abdominal mass and pain were found. She suffered from vomit after eating, severe weight loss and poor health, and she was clinically diagnosed as intestinal obstruction induced by abdominal adhesions. After <NUM>×<NUM> of HA fragment injections via abdominal subcutaneous fat layer, all the above symptoms and signs disappeared, intestinal obstruction did not occur after eating non-liquid food, and the mental state turned better significantly. The therapeutic results suggested that the HA fragment injection eventually eliminated the symptoms and signs of abdominal adhesions maybe by reducing the inflammations in abdominal mucosa.

A <NUM>-year-old female subject underwent oophorectomy began to receive <NUM> of HA fragment injection via abdominal subcutaneous fat layer from Day <NUM> preoperatively, once a day for <NUM> consecutive days. After the operation, the mental state was obviously better than that after general operations. She could walk on the day of operation, she did not suffer from fever, she had bowel sounds and exhausted on the same day, and the postoperative wound healing was obviously better that that after general operations.

A <NUM>-year-old female subject underwent intestinal anastomosis began to receive <NUM> of HA fragment injection via abdominal subcutaneous fat layer from Day <NUM> preoperatively, once a day for <NUM> consecutive days. After the operation, the mental state was obviously better than that after general operations, she could walk slowly by holding the bed on the day of operation, she did not suffer from fever, she had bowel sounds and exhausted on the same day, and the postoperative wound healing was obviously better that that after general operations.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer or at diseased site can effectively treat pelvic mucous membrane adhesions after operation and peritoneal dialysis, effectively control the inflammatory symptoms caused by operation, obviously accelerate the postoperative rehabilitation and reduce the postoperative pain.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of endometriosis with dysmenorrhea or pelvic mucous membrane adhesion of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of endometriosis with dysmenorrhea or pelvic mucous membrane adhesion.

HA fragment injections in the treatment of dysmenorrhea or pelvic mucous membrane adhesion: Endometriosis is always accompanied by infertility and dysmenorrhea; infertility and dysmenorrhea may be associated with the inflammation and adhesion of pelvic mucous membrane; there is still no effective method for treating dysmenorrhea and endometriosis or pelvic mucous membrane adhesion; among the <NUM> subjects, we analyzed <NUM> cases of pelvic mucous membrane adhesion and dysmenorrhea (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

A <NUM>-year-old female subject suffered from serious adenomyosis, the ultrasonography showed that the uterus was obviously increased, and dysmenorrheal was very serious. She was injected with <NUM> of HA fragment via abdominal subcutaneous fat layer from the beginning of menstruation, once a day for <NUM> consecutive days, and the dysmenorrhea was obviously relieved.

A <NUM>-year-old female subject suffered from serious adenomyosis, the ultrasonography showed that the uterus was obviously increased, CA125 was obviously higher than that of normal people, and the dysmenorrhea was serious. She was injected with <NUM> of HA fragment via abdominal subcutaneous fat layer from the beginning of menstruation, once every <NUM> days for <NUM> consecutive days, and the dysmenorrhea almost disappeared during two menstruations, CA125 got normal, and ultrasonography showed that the uterus began to reduce.

A <NUM>-year-old female with infertility was found by examination to have endometriosis and ovarian cyst; after the excision by minimally invasive operation, she began to receive <NUM> of HA fragment injection via abdominal subcutaneous fat layer, once every <NUM> days for <NUM> consecutive months, and she was pregnant in the <NUM>th month.

The above results showed that the HA injections obviously relieved dysmenorrheal, and the HA injections reduced the inflammatory severity of endometriosis in pelvic cavity and the severity of referred pain induced by pelvic adhesion, indicating that the HA fragment injections may also be used for treating infertility caused by poor peristalsis of ovarian ducts induced by endometriosis and pelvic adhesion.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer are used for effectively controlling dysmenorrhea and effectively treating endometriosis with dysmenorrhea and related diseases.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indications of itching neurodermatitis, psoriasis, itching senile eczema, eczema herpeticum or pompholyx of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indications of itching neurodermatitis, psoriasis, itching senile eczema, eczema herpeticum or pompholyx.

HA fragment injections in the treatment of itching neurodermatitis, psoriasis, itching senile eczema, eczema herpeticum or pompholyx. Among the <NUM> subjects, we analyzed <NUM> cases of neurodermatitis, psoriasis, itching senile eczema, eczema herpeticum or pompholyx (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

In Table <NUM>, <NUM> subject of neurodermatitis (male, <NUM> years old) had suffered from neurodermatitis for <NUM> years, and he had bilateral symmetrical multiple skin lesions, serious itching and local inflammatory skin lesions. The subject was dissatisfied with the therapeutic effect of previous Stelara (anti-IL-<NUM>/<NUM> antibody) injection. After <NUM>×<NUM> of HA fragment injections via abdominal subcutaneous fat layer, the itching almost disappeared, the inflammatory skin lesions almost recovered (<FIG>), and the subject was satisfied with the effect.

In Table <NUM>, <NUM> subject of psoriasis (male, <NUM> years old) had suffered from psoriasis for <NUM> years, and he had multiple local inflammatory skin lesions and thickening of skin lesions in abdomen and the upper and lower limbs, accompanied by the itching symptom. The subject was dissatisfied with the therapeutic effect of Stelara (anti-IL-<NUM>/<NUM> antibody) injection <NUM> years ago. After <NUM>×<NUM> of HA fragment injections via abdominal subcutaneous fat layer, the itching almost disappeared, the thickened skin lesions obviously became thinner, the inflammatory skin lesions were obviously recovered (<FIG>), and the subject was satisfied with the effect.

In Table <NUM>, <NUM> subject of psoriasis (female, <NUM> years old) had suffered from psoriasis for <NUM> years, she had multiple local inflammatory skin lesions and thickening of skin lesions in abdomen and the upper and lower limbs, accompanied by the itching symptom, and cortical hormone had not been used. After <NUM>×<NUM> of HA fragment injections via abdominal subcutaneous fat layer, the itching disappeared, the skin lesions disappeared completely, and the subject was very satisfied with the effect.

In Table <NUM>, <NUM> subject of pompholyx (female, <NUM> years old) had suffered from pompholyx for <NUM> years, and it attacked every summer. After <NUM>×<NUM> of HA fragment injections via abdominal subcutaneous fat layer, pompholyx did not occur during injection and within <NUM> year after injection.

The results of Tables <NUM> and <NUM> showed that the HA fragment injections via abdominal subcutaneous fat layer could treat itching neurodermatitis, psoriasis, itching senile eczema, eczema herpeticum or pompholyx.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating itching neurodermatitis, psoriasis, itching senile eczema and eczema herpeticum or pompholyx.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indications of senility-related diseases of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>), including periodontal inflammation, dental ulcer, guttural inflammation, conjunctival inflammation.

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indications of senility-related diseases, including periodontal inflammation, dental ulcer, guttural inflammation, conjunctival inflammation.

Senility is defined as the functional decline of various tissues and organs, including the changes in skin and appearance and the decline of physical strength and energy. What is more outstanding is the frequent attacks of various common diseases, including senility-related periodontal inflammation, dental ulcer, guttural inflammation and conjunctival inflammation. The HA fragment injections could rapidly treat senility-related periodontal inflammation, dental ulcer, guttural inflammation and conjunctival inflammation. The frequent attacks of periodontal inflammation, dental ulcer, guttural inflammation and conjunctival inflammation in old people were senility-related diseases and were associated with the current China's environment of air pollution, drinking water pollution and greater work stress. Among the <NUM> subjects, we analyzed <NUM> cases of periodontal inflammation, dental ulcer, guttural inflammation and conjunctival inflammation (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

The results of Table <NUM> showed that the HA fragment injections had more rapid therapeutic effect on senility-related periodontal inflammation, dental ulcer, guttural inflammation and conjunctival inflammation than the previous local spray of HA fragment injection.

Conclusion: <NUM>. The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating senility-related periodontal disease and dental ulcer, including the periodontal diseases and dental ulcer induced by chemotherapy and senility; <NUM>. The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating senility-related guttural diseases, including the guttural diseases induced by chemotherapy and senility; <NUM>. The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating senility-related conjunctival diseases, including the conjunctival diseases induced by chemotherapy and senility.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of ankylosing spondylitis of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of ankylosing spondylitis.

Results: HA fragment injections could effectively treat ankylosing spondylitis.

Ankylosing spondylitis is a disease of inflammatory pain and serious spinal deformation. Among the <NUM> subjects, we analyzed <NUM> cases of early ankylosing spondylitis (<NUM> cases in the experimental group <NUM> and <NUM> case in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

Early ankylosing spondylitis was a disease of inflammatory pain. The analgesic effect of the HA fragment injection treatment showed that the inflammation of ankylosing spondylitis was reduced or eliminated, suggesting that the serious spinal deformation induced by inflammation would not develop continuously.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer are used for effectively treating painful early ankylosing spondylitis.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of recovery of physical strength and energy after chemotherapy for tumor of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of recovery of physical strength and energy after chemotherapy for solid tumors.

HA fragment injection used for recovery of physical strength and energy after chemotherapy for tumor: Among the <NUM> subjects, we analyzed <NUM> cases requiring for the recovery of physical strength and energy after chemotherapy for tumor (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer aroused for recovering physical strength and energy and effectively alleviating chemotherapy-related mucous complications after chemotherapy for different tumors.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of lung cancer of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of lung cancer.

HA fragment injection used for treating late lung cancer: Among the <NUM> subjects, we analyzed <NUM> cases with late lung cancer underwent chemotherapy combined with HA fragment injection (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once every <NUM>-<NUM> days for <NUM> consecutive months or till the death), and the results were as shown in Table <NUM>:.

In Table <NUM>, a <NUM>-year-old female subject was diagnosed with lung cancer of the right lung, accompanied by lymphatic metastasis of the left lung, brain, bone and mediastinum, which was inoperable for excision, and she was treated by radiotherapy and Tarceva chemotherapy. The subject was very weak after radiotherapy and chemotherapy, and started to receive <NUM> of HA fragment injection via abdominal subcutaneous fat layer, once every <NUM>-<NUM> days. The physical strength and energy of the subject began to recover on Day <NUM> of injection. After <NUM> months of injection, the CT examination showed that the tumor and metastatic mass were reduced. After <NUM> months of injection, she still lived normally at home and did not need hospitalization.

The therapeutic results showed that the HA fragment injection could prevent the development and further metastasis of lung cancer and significantly prolong the survival.

In Table <NUM>, a <NUM>-year-old male subject was diagnosed with lung cancer of the right lung, accompanied by the lymphatic metastasis of mediastinum, which was inoperable for excision, and the molecular testing showed that the targeted drug chemotherapy would have no significant effect. The subject was still treated with chemical drugs, and started to receive <NUM> of HA fragment injection via abdominal subcutaneous fat layer, once every <NUM> days for a total of <NUM> months. The physical strength and energy of the subject began to recover on Day <NUM> of injection. After <NUM> months of injection, the CT examination showed that the tumor and metastatic mass were reduced. After <NUM> months of injection continuously, he still lived normally at home, the CT examination showed that the reduced tumor and metastatic mass did not develop further, and it was unnecessary to hospitalize for further treatment. The therapeutic results showed that the HA fragment injection could prevent the development and further metastasis of lung cancer.

HA fragment injections used for treating early lung cancer: Among the <NUM> subjects, we analyzed <NUM> cases of early lung cancer underwent operation combined with chemotherapy and HA fragment injection (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once every <NUM>-<NUM> days for <NUM> consecutive months from <NUM> week preoperatively), and the results were as shown in Table <NUM>:.

Conclusion: <NUM>. The experimental results show that the HA fragment injections can prevent the development and further metastasis of late lung cancer; <NUM>. The experimental results also show that the HA fragment injections could prevent the relapse of early lung cancer after operation.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of pancreatic cancer of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of pancreatic cancer.

Pancreatic cancer as a quite malignant tumor develops rapidly after metastasis, and it will lead to death within <NUM> days to the fastest. Foreign researches have shown that inflammation and tumor-related inflammatory cells may be the important stimulatives for the development and metastasis of pancreatic cancer.

HA fragment injections used for treating late pancreatic cancer: Among the <NUM> subjects, we analyzed <NUM> cases of late pancreatic cancer underwent operation combined with chemotherapy and HA fragment injections (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once every <NUM>-<NUM> days for <NUM> consecutive months or till the death from <NUM> weeks preoperatively), and the results were as shown in Table <NUM>:.

In Table <NUM>, a subject (male, <NUM> years old) after chemotherapy for pancreatic head cancer after chemotherapy was found that the pancreatic head cancer had transferred to liver due to jaundice, the bile duct was blocked to result in jaundice, the jaundice was solved by placing a stent through operation and nasobiliary drainage. He received chemotherapy monthly and was treated by traditional Chinese medicine at the same time. After <NUM>×<NUM> of HA fragment injections via abdominal subcutaneous fat layer, the physical strength and energy recovered; after <NUM>×<NUM><NUM> of HA fragment injections via abdominal subcutaneous fat layer, the ultrasonography showed that the pancreatic head cancer and the metastatic mass to liver began to reduce, and the subject worked normally for more than <NUM> days. The above results suggested that the HA fragment injection could promote the recovery of physical strength and energy after chemotherapy for solid tumors and might prevent the development and further metastasis of pancreatic head cancer by inhibiting inflammations. According to a foreign report (Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer at: http://www. com/Investors/News-Releases/News-Release-Details/<NUM>/Hal ozyme-Receives-Orphan-Drug-Designation-For-PEGylated-Recombinant-Human-Hy aluronidase-PH20-For-Pancreatic-Cancer/default. aspx#sthash. dpuf), long-acting hyaluronidase PEGPH20 combined with chemotherapy effectively prolongs the survival of patients with pancreatic cancer, and the experimental results indicate that the mechanism of action might be that the LMW-HA fragment injection similar to the invention is produced using HA in human body.

Conclusion: The experimental results show that the HA fragment injections can prevent the development and further metastasis of late pancreatic cancer and obviously prolong the survival.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of gastric cancer of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of gastric cancer.

HA fragment injections used for treating late gastric cancer: Among the <NUM> subjects, we analyzed <NUM> cases of late gastric cancer underwent operation combined with chemotherapy and HA fragment injections (<NUM> cases in the experimental group <NUM> and <NUM> case in the experimental group <NUM>, once every <NUM>-<NUM> days for > <NUM> consecutive months), and the results were as shown in Table <NUM>:.

In Table <NUM>, a subject (male, <NUM> years old) after chemotherapy for gastric cancer had multiple metastasis of gastric cancer, and the metastatic mass in brain compressed the respiratory center to cause dyspnea, and he was rescued in the ICU. He was treated by <NUM> of HA fragment injection via abdominal subcutaneous fat layer, once a day for <NUM> consecutive days. At Day <NUM> after HA fragment injection, the subject breathed smoothly with the physical strength and energy recovered, and he was discharged to go home for rehabilitation. After discharge, the subject was injected with <NUM> of HA fragment injection via abdominal subcutaneous fat layer at home, once every <NUM>-<NUM> days for <NUM> consecutive months or more.

Conclusion: The experimental results show that the HA fragment injections can prevent the development and further metastasis of late gastric cancer and obviously prolong the survival.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of ovarian cancer of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of ovarian cancer.

Results: HA fragment injection used for treating late ovarian cancer: Among the <NUM> subjects, we analyzed <NUM> cases of late ovarian cancer underwent chemotherapy combined with HA fragment injection (<NUM> cases in the experimental group <NUM> and <NUM> case in the experimental group <NUM>, once every <NUM> days for <NUM> consecutive months), and the results were as shown in Table <NUM>:.

In Table <NUM>, a subject (female, <NUM> years old) after operation and chemotherapy for ovarian cancer was extremely weak due to the chemotherapy and radiotherapy for lymphatic metastasis, and she had to stay in bed all day. She was injected with <NUM>× <NUM> of HA fragment injections via abdominal subcutaneous fat layer, the physical strength and energy began to recover on Day <NUM> after <NUM>×<NUM>; at the end of <NUM>×<NUM> injections, CA125 was surprisingly reduced to 50U/ml from <NUM> U/ml before treatment, and the tumor and metastatic mass were reduced, indicating that the HA fragment injection could promote the recovery of physical strength and energy after chemotherapy for treating ovarian cancer and might prevent the development and further metastasis of ovarian cancer by inhibiting inflammations.

Conclusion: The experimental results show that the HA fragment injections can lower CA125 as a cancer indicator for late ovarian cancer and control the continuous growth and metastasis of late ovarian cancer or the metastatic mass of late ovarian cancer.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of oral cancer with difficulty in eating of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of oral cancer with difficulty in eating.

Results: HA fragment injections used for treating oral cancer: Among the <NUM> subjects, we analyzed <NUM> cases of oral cancer with obvious difficulty in eating treated by HA fragment injection (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once a day for <NUM> injections consecutively for those in the experimental group in the Table, and injection of normal saline + oral administration of antibiotics metronidazole for those in the control group), and the results were as shown in Table <NUM>:.

Conclusion: The experimental results show that the HA fragment injections can be used for treating oral cancer with obvious difficulty in eating.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of postoperative relapse of meningioma of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of postoperative relapse of meningioma.

HA fragment injection used for treating postoperative relapse of meningioma: Among the <NUM> subjects, we analyzed <NUM> cases of postoperative relapse of meningioma treated by HA fragment injection (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once every <NUM>-<NUM> day for <NUM> consecutive months) , and the results were as shown in Table <NUM>:.

Conclusion: The experimental results show that the HA fragment injections can control the postoperative relapse of meningioma.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of functional recovery after cerebral embolism of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of functional recovery after cerebral embolism.

Result <NUM>: HA fragment injection used for functional recovery after cerebral embolism: Among the <NUM> subjects, we analyzed <NUM> cases requiring for functional recovery for the stiffness of upper limbs after cerebral embolism (<NUM> cases in the experimental group <NUM>, <NUM> injection every <NUM> days for <NUM> times consecutively), and the results were as shown in Table <NUM>:.

In Table <NUM>, <NUM> male subject (<NUM> years old) had suffered from cerebral embolism for <NUM> years, and he had the feel of cold on the whole body, stiffness of upper limbs and failure in relaxing fingers. After <NUM>×<NUM> HA fragment injections via abdominal subcutaneous fat layer, the symptoms and signs of feel of cold on the whole body, stiffness of upper limbs and failure in relaxing fingers obviously turned better, and he required to receive the HA fragment injection continuously.

In Table <NUM>, <NUM> male subject (<NUM> years old) had suffered from cerebral embolism for <NUM> years, and he had the stiffness of upper limbs, failure in relaxing fingers and pain in fingers. After <NUM>×<NUM> HA fragment injections via abdominal subcutaneous fat layer, the symptoms and signs of stiffness of upper limbs and failure in relaxing fingers obviously turned better.

In Table <NUM>, <NUM> male subject (<NUM> years old) had suffered from cerebral embolism for <NUM> year, and he had the stiffness of upper limbs, failure in relaxing fingers and numbness in fingers. After <NUM>×<NUM> HA fragment injections via abdominal subcutaneous fat layer, the symptoms and signs of stiffness of upper limbs, failure in relaxing fingers and numbness in fingers obviously turned better.

Result <NUM>: HA fragment injections used for functional recovery after cerebral embolism: Among the <NUM> subjects, we analyzed <NUM> cases requiring for functional recovery for the weakness of upper limbs after cerebral embolism (<NUM> case in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>), and the results were as shown in Table <NUM>:.

In Table <NUM>, <NUM> male subject (<NUM> years old) had suffered from cerebral embolism for <NUM> days, and he was weak in half body and feeble in walking. After <NUM>×<NUM> HA fragment injections via abdominal subcutaneous fat layer, the weakness in half body obviously turned better, and he was strong to walk, indicating that the HA fragment injection could be used for the functional recovery after cerebral embolism.

In Table <NUM>, <NUM> male subject (<NUM> years old) had suffered from cerebral embolism for <NUM> days, and he could only see the objects within <NUM> due to the impaired vision. After <NUM>×<NUM> HA fragment injections via abdominal subcutaneous fat layer, the vision obviously turned better, and he could see the objects within <NUM>, indicating that the HA fragment injection could be used for the functional recovery after cerebral embolism.

Conclusion: The HA fragment injections via abdominal subcutaneous fat layer can effectively promote the functional recovery after cerebral embolism.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of angina of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of angina.

HA fragment injections used for treating angina induced by cardiovascular diseases: Coronary heart disease, complications after intravascular stent and other cardiovascular diseases are essentially chronic inflammatory diseases, and the effective methods for prevention and treatment are in urgent need. Among the <NUM> subjects treated by HA fragment injections, we analyzed <NUM> cases of angina (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once a day for <NUM> injections consecutively), and the results were as shown in Table <NUM>:.

Conclusion: The results of Table <NUM> show that the HA fragment injection via abdominal subcutaneous fat layer can effectively treat the angina induced by cardiovascular diseases.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of painful gout during attack of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indications of painful gout during attack.

HA fragment injections used for treating gout: Among the <NUM> subjects treated by HA fragment injections, we analyzed <NUM> cases of painful gout during attack (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once a day for <NUM> times consecutively), and the results were as shown in Table <NUM>:.

Conclusion: The results of Table <NUM> showed that the HA fragment injection via abdominal subcutaneous fat layer can effectively treat painful gout during attack.

Objetive: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of arthritis never treated by cortical hormone of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of arthritis never treated by cortical hormone.

HA fragment injections used for treating arthritis never treated by cortical hormone: Among the <NUM> subjects treated by HA fragment injections, we analyzed <NUM> cases of arthritis never treated by cortical hormone (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once a day for <NUM> times consecutively), and the results were as shown in Table <NUM>:.

HA fragment injections used for treating arthritis previously treated by cortical hormone: Among the <NUM> subjects treated by HA fragment injections, we analyzed <NUM> cases of arthritis previously treated by cortical hormone (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once a day for <NUM> times consecutively), and the results were as shown in Table <NUM>:.

Conclusion: <NUM>. The HA fragment injection via abdominal subcutaneous fat layer can effectively treat arthritis never treated by cortical hormone; <NUM>. The HA fragment injection via abdominal subcutaneous fat layer had no therapeutic effect on arthritis previously treated by cortical hormone.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of herpes zoster with serious pain of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of herpes zoster with serious pain.

HA fragment injections used for treating herpes zoster with serious pain: Among the <NUM> subjects treated by HA fragment injections, we analyzed <NUM> cases of herpes zoster with serious pain (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, once a day for <NUM> times consecutively), and the results were as shown in Table <NUM>:.

Conclusion: The results of Table <NUM> show that the HA fragment injections via abdominal subcutaneous fat layer can effectively treat herpes zoster with serious pain.

Objective: To further analyze the changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>", and to identify the new clinical indication of acute pancreatitis with serious pain of the HA fragment injections (HA fragment Injections <NUM> and <NUM> in Embodiment <NUM>).

Methods: The changes in the diseases and subclinical problems of the <NUM> subjects before and after treatment with HA fragment injections in "Embodiment <NUM>" were further analyzed, including medical history, symptoms, signs and laboratory results before injection, and the changes in symptoms, signs and laboratory results after the HA fragment injections, so as to identify the therapeutic effect of the HA fragment injections on the new clinical indication of acute pancreatitis with serious pain.

HA fragment injections used for acute pancreatitis with serious pain: Among the <NUM> subjects treated by HA fragment injections, we analyzed <NUM> cases of acute pancreatitis with serious pain (<NUM> cases in the experimental group <NUM> and <NUM> cases in the experimental group <NUM>, in the table below, the experimental groups were injected with HA fragment injection + antibiotics for once a day, and the control group was injected with antibiotics for once a day, for <NUM> injections consecutively), and the results were as shown in Table <NUM>:.

Conclusion: The results of Table <NUM> show that the HA fragment injection via abdominal subcutaneous fat layer can effectively treat acute pancreatitis with serious pain.

Objective: To compare the studies on subcutaneous injection of LMW-HA fragments produced by different methods on dogs and human subjects. Methods: In Embodiment <NUM> of the invention, the HMW-HA raw material was directly digested using human recombinant hyaluronidase to produce HA fragment Injection <NUM> and Injection <NUM> (with a molecular weight distribution of <NUM>-60KD), and the injection deep into abdominal subcutaneous fat layer did not cause pain in the above embodiment.

In the previous research achievement (<CIT>) of the applicant, it is also recorded that HMW-HA raw material was firstly baked and heated to reduce the molecular weight of HMW-HA raw material, and then HMW-HA was digested by recombinant human hyaluronidase to produce the LMW-HA fragments.

In this embodiment, the step of baking HMW-HA raw material is added in reference to the above method. The baking aims to reduce the molecular weight of HMW-HA raw material and reduce the viscosity after dissolution using the physical method. Besides, owing to the reduction in the molecular weight of HMW-HA raw material after baking, the amount of recombinant human hyaluronidase used for subsequent digestion can be further reduced to greatly lower the cost.

In implementation, except the baking step, the rest of steps are the same as those in Embodiment <NUM>. Specifically, the process of implementation can follow the specific steps below:.

The HA fragment injection was prepared after filtration, comprising:.

The LMW-HA fragment Injection <NUM> and Injection <NUM> as well as Injection <NUM> in the above embodiment produced by different methods were used for subcutaneous injection on dogs and human, and it was found that Injection <NUM> induced the side effect of pain in injection. The pain in dogs was demonstrated by the fierce flounder at the beginning of injection and in the process of injection, and the pain in subjects was demonstrated by complaining about the pain to the injector and requiring stopping the injection immediately.

Conclusion: <NUM>. Unexpectedly, the subcutaneous injection of LMW-HA fragments produced by baking at <NUM> causes serious pain for dogs and subjects, and it can't be used for injection; <NUM>. Unexpectedly, the subcutaneous injection of LMW-HA fragments produced by baking at <NUM> does not cause pain for dogs and subjects, and it can be used for injection (the injection also has a therapeutic effect on the above diseases or symptoms in subjects only with enough sample number in order to achieve statistical significance, and the specific results are not listed here. Besides, in consideration to the production cost, the HA fragment injection produced by this production method is applicable for developing into products for experimental animals or for veterinary use. The subcutaneous injection of LMW-HA fragments produced without baking and directly by enzyme digestion using recombinant human hyaluronidase does not cause pain for dogs and subjects, and it can be used for injection.

Objective: To explore the possibility for activation and commercialized production of LMW-HA fragments with the therapeutic effect in the above embodiments by the digestion using other types of hyaluronidase.

Methods: (<NUM>) Study the production methods of multiple hyaluronidases and the results of producing LMW-HA fragments by enzyme digestion of HMW-HA found in the existing references; (<NUM>) Produce different hyaluronidases independently or cooperatively, and verify the feasibility in enzyme digestion and activation of HMW-HA; (<NUM>) Study what kind of hyaluronidase can digest and activate HMW-HA to the corresponding molecular weight? Which kind of end structure of enzyme digestion can activate LMW-HA to have the therapeutic effect of the HA fragment injections shown in the above embodiments? Which kind of hyaluronidase residue will not cause allergic reaction in human?.

Results and Discussions: By combining with the production methods of multiple hyaluronidases and the methods for enzyme digestion of HMW-HA, the research results are respectively reported as below:.

In addition to neutral human acrosome hyaluronidase PH20 (or Hyal3 or SPAM1) in this study, human also has hyaluronidase Hyal1 and Hyal2 in cells. According to the reference "<NPL>", it has been found that recombinant human Hyal1 hyaluronidase produced by insect cell Drosophila Schneider-<NUM> (DS-<NUM>) has the specific activity of <NUM> U/mg and the best reaction pH value of <NUM>-<NUM>, but such production method has a very low output, and it is not applicable for activation and commercialized production of LMW-HA fragment injection. In addition, we produce recombinant human Hyal1 and Hyal2 proteins using zooblast (CHO-S cells), pMH3, pMH4 and pMH5 expression vectors rich in GC, and human Hyal1 and Hyal2 cDNA by the construction manner of the expression system in Embodiment <NUM>. It is found that the activities of the obtained hyaluronidases Hyal1 and Hyal2 are significantly lower than PH20 (<NUM>×<NUM> U/mg zymoprotein) produced at present, indicating that the recombinant human Hyal1 and Hyal2 are not applicable for producing zooblasts. The output of yeast-expressed neutral human acrosome hyaluronidase PH20 (or Hyal3 or SPAM1) can reach the level of commercialization, with the specific activity up to <NUM>,<NUM> IU/mg zymoprotein, and it is applicable for digestion, activation and commercialized production of LMW-HA fragment injection. We use the yeast-expressed neutral human acrosome hyaluronidase PH20, after enzyme digestion, affinity column chromatography, precipitation, column chromatography, dialysis, ultrafiltration concentration, etc. are used in order or respectively for recombinant human hyaluronidase to remove the contained protein residue of recombinant human hyaluronidase and produce the HA fragment injection similar to HA fragment Injection <NUM> in Embodiment <NUM> (HA fragments with a molecular weight distribution of 10KD-60KD <NUM>/<NUM>-<NUM>, <NUM>-<NUM> of sodium chloride and <NUM> of magnesium ions) not containing protein residue of recombinant human hyaluronidase, and a clinical study was carried out for <NUM> subjects of multiple senility-related diseases. According to the results of Table <NUM>, although yeast-expressed neutral human acrosome hyaluronidase PH20 had a lower specific activity, it had certain influence on the purity of HA fragment injection, and it could be used for producing HA fragment injection having a therapeutic effect on human and without allergic side effect by removing the contained protein residue of recombinant human hyaluronidase.

We produce the fusion protein of neutral human acrosome hyaluronidase PH20 from the oily seed expression system using the plant of Arabidopsis thaliana through a partner laboratory, and it is found that it can be used for producing the above HA fragment injection having a therapeutic effect on human and without allergic effect; see Table <NUM> for the specific effects. Compared with the high-purity glycosylated recombinant human hyaluronidase produced from the zooblast of Chinese hamster ovary cells, this method for producing the fusion protein of hyaluronidase PH20 has low cost, high output and low activity, but the cost is slightly higher for removing the contained fusion protein of hyaluronidase PH20. In addition, based on our previous research achievements in LMW-HA for external use, we believe that the plant expressed hyaluronidase PH20 is applicable for producing LMW-HA aerosol, spray, gel preparations, etc. for external use requiring for low purity.

The hyaluronidase extracted from goat or bovine testes is mainly neutral goat or bovine acrosome hyaluronidase PH20, and the skin allergy test is required before use for human. Though such hyaluronidase has low cost, it also has low purity, and the cost is also high for removing the protein residues of hyaluronidase. Compared with high-purity glycosylated recombinant human hyaluronidase produced from the zooblast of Chinese hamster ovary cells, it is believed that it is not applicable for producing the HA fragment injection having a therapeutic effect on human, without allergic side effect and requiring for high purity. According to the Patent <CIT>, LMW-HA less than 10KD generated by streptococci hyaluronidase does not cause inflammatory reactions, but LMW-HA greater than 10KD generated by Streptomyces hyaluronidase causes inflammatory reactions, and these are contradictive to our HA fragment with a molecular weight distribution of 10KD-60KD having a therapeutic effect; however, it shall be mainly considered here that the protein residue of bacterial hyaluronidase may induce allergic reactions for human, and it is not applicable for producing the HA fragment injection having a therapeutic effect on human, without allergic side effect and requiring for high purity. Hyaluronidase bee venom has strong allergen property, and it can cause allergic reaction for human in addition to promoting the absorption of bee venom. The hyaluronidase extracted from bee venom and the microorganism-expressed hyaluronidase in bee venom are both not applicable for producing the HA fragment injection having a therapeutic effect on human, without allergic side effect and requiring for high purity. Leech hyaluronidase secreted by hematophagous leech can dissolve skin and help the leech enter human body to suck blood. According to the references of "<NPL>" and "<NPL>", the yield, digestion activity and cust of the fusion protein of leech hyaluronidase in yeast expression can meet the requirement for commercialization and can digest HMW-HA into LMW-HA. However, the residue of leech hyaluronidase can cause allergic reactions, and it can be used for producing the HA fragment injection having a therapeutic effect on human shown in the above embodiments, without allergic side effect and requiring for high purity only by complete elimination.

Claim 1:
A pharmaceutical composition for injection via abdominal subcutaneous fat layer comprising low molecular weight hyaluronic acid (LMW-HA) fragments, wherein LMW-HA fragments have a molecular weight distribution of <NUM>-60KD and are obtained by use of recombinant human hyaluronidase PH20 directly digesting high-molecular-weight hyaluronic acid (HMW-HA) raw material, wherein the injection is a liquid preparation, which is prepared by the following steps:
A. Prepare HMW-HA raw material into solution, introduce sodium chloride and magnesium ions, and add recombinant human hyaluronidase PH20 for digestion to obtain the bulk injectable solution containing HA fragments with a molecular weight distribution of <NUM>-60KD;
B. Inactivate the residual recombinant human hyaluronidase PH20 in the obtained bulk injectable solution;
C. Inactivate viruses and remove bacteria through <NUM> filtration or inactivate bacteria.